Oncology

Cancer: treatment hinges on regional coordination – waits of up to 13 months for a new therapy

Focus on disparities in access and the failure to utilise 3 billion from the Innovative Medicines Fund over nine years: Aiom oncologists highlight the need for equity for the 390,000 new cases each year

 Jørgsson Photography - stock.adobe.com

6' min read

Translated by AI
Versione italiana

6' min read

Translated by AI
Versione italiana

A three-day event dedicated to the theme of equity: this means making full use of the most innovative treatments, which in Italia are supported by a dedicated fund that is not currently being fully utilised, but also drastically reducing the time it takes for patients across the country to gain access, on an equal footing, to new treatments authorised for reimbursement by the Italian Medicines Agency (AIFA). These are the issues at the heart of the Italian Association of Medical Oncology (AIOM), which is meeting in Rome from today for its 28th National Congress. The data paint a picture that clearly leaves room for improvement and which, in fact, impacts the fairness of access to treatment for the 390,000 people who are diagnosed with the disease each year in the country and for the approximately 3.7 million people living with the disease. There are two figures to highlight in red: 400 days, which is the maximum waiting time for a patient (and their carer) to receive a new treatment; 3 billion euros, representing the resources left unused over nine years (2018–2025) from the innovative medicines fund, with an upward trend. Whilst 91 per cent of the resources were spent in 2018, by 2025 this figure had fallen to just 53 per cent.

The Aiom analysis

Most of the treatments included in the Fund are for cancer: they account for 31 of the 55 indications for 2025, amounting to 353 million euros, more than half of the total expenditure (700 million). Failure to utilise these resources may result in innovative cancer treatments being unavailable to patients, creating regional inequalities. The time between AIFA’s approval for reimbursement and the award of the procurement contract can vary from 100 to 400 days across different regions (the average time is 165 days). Among the causes are the regionalisation of care pathways, as well as the variety of procurement models and local organisational decisions, which contribute to creating inequalities in access.

Loading...

On the other hand, the length of time a treatment remains in the Fund can also have an impact, according to Aiom. The maximum duration for which a treatment is recognised as innovative is three years, with no possibility of extension, even in the absence of more effective treatments. The under-utilisation of resources is leading to cuts to the Fund. The 2026 Budget Act has stipulated that, with effect from 2026, the Fund’s resources are to be reduced by 140 million euros annually. Aiom is calling for a new model of innovation governance, one that removes local bureaucratic and administrative barriers to the immediate availability of these therapies and which, in certain cases, allows therapies to remain in the Fund for up to five years.

“Innovation can only be fully realised if all citizens can benefit from it equally, regardless of where they live or receive treatment,” explains Massimo Di Maio, President of AIOM. “Italia was among the first countries in the world to establish a comprehensive regulatory framework for the assessment of innovative medicines. Recognition by AIFA that a treatment is fully innovative entails direct access to the Fund’s resources and automatic inclusion in regional formulary lists. In reality, however, medicines that should be immediately available to all patients are, in some cases, not accessible to everyone.”

Planning your shopping

The allocation of the Fund’s resources is linked to dispensing data in AIFA’s monitoring systems, but there may be delays in the activation of the registers. ‘There is still a limited frequency of reports from AIFA to the Regions,’ continues President Di Maio, ‘whilst, at regional and local level, the communication of monthly data on the Fund’s utilisation to hospital trusts is not sufficiently timely. These information gaps hinder effective planning of hospital expenditure and activities. Consequently, regional expenditure is not accurately tracked and reimbursed in a timely manner. Furthermore, some Regions, despite the publication in the Official Gazette of the AIFA decision establishing a medicine’s full innovative status, impose further obstacles; for example, they reduce the number of prescribing centres, introduce different procurement procedures for tenders and company authorisations, or centralise stages of the process.”

Times in the Regions

The result is a significant disparity across the country in the time taken to provide access to the treatments covered by the Fund. The best-performing regions are Sicily, Campania and Tuscany, whilst the slowest are Abruzzo, Marche and Sardinia. “In reality, the picture is sometimes varied even within a single region, and it can happen that, given the same clinical conditions and level of urgency, a patient receives different treatment even from one hospital to another”, Di Maio adds. He outlines three priorities, with a view to appropriateness and sustainability: “Firstly, we need to optimise budget management because, at times, the budget for innovative medicines—which fall under the Fund—is not separated from many other expenditure items, and this can put pressure on prescribers to comply with spending limits; furthermore, timely monitoring must be carried out at all levels – central, regional and hospital; finally, planning must take into account medicines due to arrive in six months’ or a year’s time, so as to ensure that what is ‘labelled’ as an innovation can translate into concrete and timely availability for patients who need it.”

“The purpose of the Innovative Medicines Fund,” emphasises Robert Nisticò, President of the Italian Medicines Agency, “is to speed up patient access: the effort we are making is to try to harmonise matters as much as possible, and in this regard too, AIFA has initiated a dialogue with the regions to avoid overlaps and excessive bureaucracy. We have built a system capable of recognising and funding innovation: now we must make it better equipped to support it over time. We will only succeed if we place equity at the heart of our decisions, recognising it as an essential principle for reconciling the value of innovation with the sustainability and universality of the National Health Service. In oncology, the value of a treatment is not limited to the evidence available at the time of reimbursement: knowledge evolves, new benefits emerge, and we gain a better understanding of which patients can derive the greatest benefit from it. ‘Our decisions,’ emphasises Nisticò, ‘must be able to keep pace with this evolution, including through assessment and negotiation tools that are increasingly focused on the outcomes achieved in clinical practice. And national recognition of a new treatment option must translate into effective access, without regional disparities.’ ‘As AIFA, we are aware that recognising the value of innovation is only part of our responsibility. The other part is to help create the conditions so that this recognition translates into a concrete opportunity for treatment for every patient, wherever they live.’

The fast-track access provided for in the budget

A measure to speed up access to new medicines for certain categories of patients is provided for in the draft Budget Bill currently before Parliament, the details of which will only be finalised as the budget process unfolds: ‘It is a provision that reflects our commitment to social progress, which we hope will be enshrined in the Budget Act, but we will only know the details on 1 January and subsequently through the implementing decrees,’ Nisticò begins. He explains that in this way ‘we could have an additional means of providing patients with medicines that have already been authorised at European level by the EU’s CHMP and the EMA but are still under negotiation in Italia. ‘For diseases where there are no valid therapeutic alternatives and where treatment cannot be delayed,’ he adds, ‘we cannot wait for the negotiation process to run its course; we must allow the use of these medicines immediately, so that they can improve health outcomes and perhaps even generate savings. We have devoted considerable attention to the issue of early access: for the time being, this involves making 70 million available under the Innovative Medicines Fund, which will certainly not be sufficient, but – it must be said – we are talking about a three-year trial to understand how best to plan and allocate resources in the future.’

Extend the duration of participation in the Innovation Fund to 5 years

At the end of the 36-month period, the medicine remains eligible for reimbursement, but the cost is no longer covered by the Innovative Medicines Fund and falls under regional direct procurement, meaning it is included within the hospital pharmaceutical expenditure limit. ‘Innovation cannot have an expiry date that is unrelated to its clinical value,’ says Rossana Berardi, President-elect of Aiom. In oncology, three years may not be sufficient to fully assess the benefits of a new therapy, especially when results become more established over time. This is why we are calling for the inclusion of medicines in the Innovative Medicines Fund to be extended to up to five years, provided specific clinical and scientific conditions are met. This is a responsible decision, necessary to ensure continuity of care, sustainability and equitable access to the best treatment options. But it is not enough simply to fund innovation: we must make it genuinely accessible, without bureaucracy slowing down its delivery to patients,” concludes Rossana Berardi. We need clear national rules, fixed timelines for the activation of prescribing centres and procurement procedures, AIFA registers operational from the moment a medicine becomes reimbursable, and transparent monitoring tools that are also accessible to clinicians. We are not asking for fewer checks, but for more effective checks and more streamlined procedures. We must have a single objective: to ensure that the right to the best treatment does not depend on the region in which a patient lives, nor on the pace of bureaucracy.”

Copyright reserved ©
Loading...

Brand connect

Loading...

Newsletter

Notizie e approfondimenti sugli avvenimenti politici, economici e finanziari.

Iscriviti